E-Cadherin Expression as a Cell Marker in Benign and Malignant Breast Lesions
Issue: 2023 - Volume 6 [Issue 2]
Shalini Goswami *
Department of General Surgery, Jawaharlal Nehru Medical College, Aligarh, India.
Rahul Kumar Giri
Department of Surgery, Shyam Shah Medical College, Rewa, India.
Department of Surgery, Jawaharlal Nehru Medical College, Aligarh, India.
*Author to whom correspondence should be addressed.
Background: Breast cancer continues to be a major cause of morbidity and mortality throughout the world. The behaviour of breast cancer varies widely. Several parameters have been investigated to predict the prognosis in breast cancer. But still there is no single parameter that can predict prognosis in an individual patient. Among the novel prognostic markers is E-cadherin; a calcium-dependent epithelial cell adhesion molecule. Its loss has been associated with metastases, thereby providing evidence for its role as an invasion suppressor. This study was conducted to evaluate the expression of E-cadherin as epithelial cell marker in the differential diagnosis of benign and malignant breast lesions and to evaluate it’s role as a diagnostic bio marker in breast cancer.
Methods: This prospective study was carried out from November 2020 to November 2022 in the Department of Surgery, at Jawaharlal Nehru Medical College, Aligarh, India. The study was conducted on 117 patients presenting with breast lesions. A detailed history, complete physical examination and preliminary investigations were done. Histopathological examination one on formalin fixed and paraffin embedded tissue sections of breast lesion. Immunostatins for E-cadherin were employed on cases. The data was collected and analyzed using SPSS 2020.
Results: Most of the patients were below 30years of age (36.7%) and the mean age was 38.1±16.9 years. 54 patients (46.4%) were benign and 63 patients (53.6%) were malignant. Out of a total of 63 malignant breast lesions, Infiltrating ductal carcinoma Not otherwise specified (IDC NOS) was most frequent, comprising 34 cases (53.9%). We stained cases of carcinoma breast for E-cadherin. Out of 15 cases of Grade 1 IDC NOS, 11 (73.3%) showed 3+ proportion score, 3 (20.0%) cases showed 2+ score, whereas 1(6.6%) case showed 1+ score. Out of 12 cases of Grade 2 IDC NOS, 6 (50.0%) showed 3+ and 5 (41.6%) showed 2+ proportion score and 1 case (8.3%) showing 1+ score. Out of 7 cases of Grade 3 IDC NOS, 6 (85.7%) cases showed 2+ proportion score and 1 case (14.2%) showed 1+, none showed 3+ score. A statistically significant finding (p=0.0059) was seen between grade and E-cadherin score. A statistically significant (p=0.0169) between E-cadherin scoring on benign and malignant cases overall implying stronger expression of E-cadherin in benign lesions as compared to malignant ones.
Conclusion: It is concluded that expression of E-Cadherin is associated with benign or malignant nature of breast lesion, with expression stronger in benign. It has a prognostic value in IDC grading.
Keywords: E-cadherin, cancer, breast, benign, IDC NOS, grading
How to Cite
Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, Franchina T, Tuccari G, Adamo V. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. PLoS One. 2015 Jun 3;10(6):e0128368.
Deo, S.V.S., Sharma, J. & Kumar, S. GLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists. Ann Surg Oncol. 2022;29:6497–6500.
Murthy NS, Agarwal UK, Chaudhary K, Saxena S. A study on time trends in incidence of breast cancer-Indian scenario. European Journal of Cancer Care. 2007;16(2):185-186.
Nicolson GL. Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochemica et biophysica Acta 1988; 948:175-224.4. Barresi V. Colorectal Cancer: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2021 Dec 8;9(12):1858.
Coman DR. Adhesiveness and stickiness: two independent properties of the cell surface, Cancer Res. 1961;21 (1): 1436-1438.
Oka HI, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-Cadherin Cell Adhesion Molecules in Human Breast Cancer Tissues and Its Relationship to Metastasis. Cancer Res. 1993;53(1):1696-1701.
Kurata A, Yamada M, Ohno SI, Inoue S, Hashimoto H, Fujita K, Takanashi M, Kuroda M. Expression level of microRNA-200c is associated with cell morphology in vitro and histological differentiation through regulation of ZEB1/2 and E-cadherin in gastric carcinoma. Oncol Rep. 2018 Jan;39(1):91-100.
McCart Reed AE, Kutasovic JR, Nones K, Saunus JM, Da Silva L, Newell F, et al. Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology. J Pathol. 2018 Apr;244(4): 460-468.
Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-Cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci. 2011 May;3(5):227- 33.
Qureshi HS, Linden MD, Divine G and Raju UB. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters, Am J Clin Pathol. 2006;125(3):377-385.
Suciu C, Cîmpean AM, Muresan AM, Izvernariu D, Raica M. E-cadherin expression in invasive breast cancer. Romanian Journal of Morphology and Embryology. 2008;49(4):517-523.